News & Updates

Low-dose rivaroxaban more harmful than beneficial in advanced CKD patients at high CV risk

The use of low-dose rivaroxaban among patients with advanced chronic kidney disease (CKD) and high cardiovascular (CV) risk does little to reduce the risk of adverse CV events and may even contribute to increased bleeding events, according to the TRACK randomized clinical trial.

EMERALD-3: Unresectable liver cancer gets PFS benefit with treatment combination strategies

In the treatment of patients with unresectable embolization-eligible hepatocellular carcinoma (eeHCC), combining transarterial chemoembolization (TACE) with the immunotherapy-based STRIDE (single tremelimumab regular interval durvalumab) regimen with or without lenvatinib substantially increases progression-free survival (PFS), as shown in the global phase 3 EMERALD-3 study.

DSC3-targeted immunotherapy shows promise in recurrent/metastatic HNSCC

Immunotherapy directed at desmocollin-3 (DSC3) safely improves outcomes in patients with recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) expressing DSC3, reports a study presented at ASCO 2026.

Flu vax may be safely co-administered with pertussis-containing vaccine during pregnancy

Administering influenza vaccine concomitantly with pertussis-containing vaccine during pregnancy does not contribute to increased risk of adverse pregnancy outcomes, as reported in a retrospective study.

[Infographics] STRIDE vs atezolizumab + bevacizumab in 1L HCC – is there any difference in OS

Focusing on dual immunotherapy in unresectable HCC:

• STRIDE (single tremelimumab regular interval durvalumab) is the first and only IO regimen to date with 6-year OS data in unresectable HCC.¹

• In the HIMALAYA study, STRIDE was compared vs sorafenib and achieved a 1.9 times higher 6-year OS rate.¹

• Real-world data indicate that there are no significant differences between STRIDE and atezolizumab + bevacizumab as 1L therapies for advanced HCC, showing them to be equally valid options for patients with advanced HCC.²

Original New Drug Application Approvals by US FDA (16-31 May 2026)

New drug applications approved by US FDA as of 16-31 May 2026 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (1-15 May 2026)

New drug applications approved by US FDA as of 1-15 May 2026 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

High-dose influenza vaccine linked to reduced hospitalization risk in older adults

High-dose inactivated influenza vaccine (HD-IIV) confers improved protection against hospitalization outcomes for older adults when compared with standard-dose inactivated influenza vaccine (SD-IIV), according to the results of a meta-analysis.

Frontline ivonescimab plus chemo ups survival in advanced squamous NSCLC

In the first-line treatment of patients with advanced squamous non-small cell lung cancer (NSCLC) in China, the combination of ivonescimab plus chemotherapy significantly improves overall survival (OS) compared with tislelizumab plus chemotherapy, according to the phase III HARMONi-6 trial.